[논문]Isolation and Antimicrobial Susceptibility of Nontuberculous Mycobacteria in a Tertiary Hospital in Korea, 2016 to 2020

Keun Ju Kim; Seung-Hwan Oh; Doosoo Jeon; Chulhun L. Chang

doi:10.4046/trd.2022.0115

Isolation and Antimicrobial Susceptibility of Nontuberculous Mycobacteria in a Tertiary Hospital in Korea, 2016 to 2020 원문보기

Tuberculosis and respiratory diseases : TRD = 결핵 및 호흡기 질환, v.86 no.1, 2023년, pp.47 - 56

Keun Ju Kim (Department of Laboratory Medicine, Korea University Anam Hospital, Korea University College of Medicine) , Seung-Hwan Oh (Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital) , Doosoo Jeon (Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicin) , Chulhun L. Chang (Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital)

Abstract ▼ AI-Helper

Background: There is a global increase in isolation of nontuberculous mycobacteria (NTM). The aim of the study was to analyze longitudinal trends of NTM identification and pattern of antimicrobial susceptibility testing. Methods: NTM recovery rates, distribution of NTM species identification, and antimicrobial susceptibility pattern of NTM at Pusan National University Yangsan Hospital between January 2016 and December 2020 were retrospectively analyzed. Results: A total of 52,456 specimens from 21,264 patients were submitted for mycobacterial culture, of which 2,521 from 1,410 patients were NTM positive over five years (January 2016 to December 2020). NTM isolation showed an increasing trend from 2016 to 2020 (p<0.001, test for trend) mainly caused by Mycobacterium avium complex. The vast majority of M. avium complex were susceptible to key agents clarithromycin and amikacin. For Mycobacterium kansasii, resistance to rifampin and clarithromycin is rare. Amikacin was the most effective drug against Mycobacterium abscessus subspecies abscessus and Mycobacterium subspecies massiliense. Most of M. subspecies massiliense were susceptible to clarithromycin, while the majority of M. abscessus subspecies abscessus were resistant to clarithromycin (p<0.001). Conclusion: There was an increasing trend of NTM isolation in our hospital. Resistance to key drugs was uncommon for most NTM species except for M. abscessus subspecies abscessus against clarithromycin.

주제어

표/그림 (7)

그림 Figure 2. Annual proportion of nontuberculous mycobacteria (NTM) from positive culture isolates.
그림 Figure 1. Annual isolation rate of nontuberculous mycobacteria among total clinical specimens compared to Mycobacterium tuberculosis .
표 Table 1. List of identified nontuberculous mycobacteria species recovered from clinical isolates during 2016 to 2020 (n=718)
그림 Figure 3. Annual proportion of nontuberculous mycobacteria (NTM) species identification (n=718). M. massiliense : Mycobacterium abscessus subspecies massiliense ; M. abscessus : Mycobacterium abscessus subspecies abscessus .
표 Table 2. Antimicrobial susceptibility testing results for Mycobacterium avium complex
표 Table 3. Antimicrobial susceptibility testing results for Mycobacterium kansasii
표 Table 4. Antimicrobial susceptibility testing results for Mycobacterium abscessus complex

참고문헌 (54)

1 Jeon D Infection source and epidemiology of nontuberculous mycobacterial lung disease Tuberc Respir Dis (Seoul) 2019 82 94 101 30302953
2 Kim HS Lee Y Lee S Kim YA Sun YK Recent trends in clinically significant nontuberculous Mycobacteria isolates at a Korean general hospital Ann Lab Med 2014 34 56 9 24422197

상세보기
3 Kim N Yi J Chang CL Recovery rates of non-tuberculous mycobacteria from clinical specimens are increasing in Korean tertiary-care hospitals J Korean Med Sci 2017 32 1263 7 28665061

상세보기
4 Cowman S Burns K Benson S Wilson R Loebinger MR The antimicrobial susceptibility of non-tuberculous mycobacteria J Infect 2016 72 324 31 26723913

상세보기
5 Adjemian J Olivier KN Seitz AE Holland SM Prevots DR Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries Am J Respir Crit Care Med 2012 185 881 6 22312016

상세보기
6 Martin-Casabona N Bahrmand AR Bennedsen J Thomsen VO Curcio M Fauville-Dufaux M Non-tuberculous mycobacteria: patterns of isolation: a multi-country retrospective survey Int J Tuberc Lung Dis 2004 8 1186 93 15527150
7 Shah NM Davidson JA Anderson LF Lalor MK Kim J Thomas HL Pulmonary Mycobacterium avium-intracellulare is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007-2012 BMC Infect Dis 2016 16 195 27154015
8 Johansen MD Herrmann JL Kremer L Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus Nat Rev Microbiol 2020 18 392 407 32086501

상세보기
9 Saxena S Spaink HP Forn-Cuni G Drug resistance in nontuberculous mycobacteria: mechanisms and models Biology (Basel) 2021 10 96 33573039

상세보기
10 Sim YS Park HY Jeon K Suh GY Kwon OJ Koh WJ Standardized combination antibiotic treatment of Mycobacterium avium complex lung disease Yonsei Med J 2010 51 888 94 20879056

상세보기
11 Wallace RJ Dukart G Brown-Elliott BA Griffith DE Scerpella EG Marshall B Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections J Antimicrob Chemother 2014 69 1945 53 24633206

상세보기
12 Griffith DE Aksamit T Brown-Elliott BA Catanzaro A Daley C Gordin F An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases Am J Respir Crit Care Med 2007 175 367 416 17277290

상세보기
13 Mirsaeidi M Farshidpour M Allen MB Ebrahimi G Falkinham JO Highlight on advances in nontuberculous mycobacterial disease in North America Biomed Res Int 2014 2014 919474 25574470

상세보기
14 van Ingen J Boeree MJ van Soolingen D Mouton JW Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria Drug Resist Updat 2012 15 149 61 22525524
15 Research Committee of the British Thoracic Society First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol Thorax 2001 56 167 72 11182006
16 Woods GL Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes: CLSI supplement M62 1st ed Wayne Clinical and Laboratory Standards Institute 2018
17 Griffith DE Aksamit TR Managing Mycobacterium avium complex lung disease with a little help from my friend Chest 2021 159 1372 81 33080299

상세보기
18 Kwon BS Kim MN Sung H Koh Y Kim WS Song JW In vitro MIC values of rifampin and ethambutol and treatment outcome in Mycobacterium avium complex lung disease Antimicrob Agents Chemother 2018 62 e00491 18 30012759
19 Moon SM Kim SY Kim DH Huh HJ Lee NY Jhun BW Relationship between resistance to ethambutol and rifampin and clinical outcomes in Mycobacterium avium complex pulmonary disease Antimicrob Agents Chemother 2022 66 e0202721 35266825

상세보기
20 Woods GL Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes: CLSI standard M24 3rd ed Wayne Clinical and Laboratory Standards Institute 2018
21 Park Y Park YE Jhun BW Park J Kwak N Jo KW Impact of susceptibility to injectable antibiotics on the treatment outcomes of Mycobacterium abscessus pulmonary disease Open Forum Infect Dis 2021 8 ofab215 34189168

상세보기
22 Basille D Jounieaux V Andrejak C Treatment of other nontuberculous mycobacteria Semin Respir Crit Care Med 2018 39 377 82 30071552

상세보기
23 Global Laboratory Initiative Mycobacteriology laboratory manual 1st ed Geneva Global Laboratory Initiative 2014
24 Kim SH Shin JH Identification of nontuberculous mycobacteria from clinical isolates and specimens using AdvanSure Mycobacteria GenoBlot assay Jpn J Infect Dis 2020 73 278 81 32213717
25 Petti CA Brandt ME Church DL Emler S Simmon K Zelazny AM Interpretive criteria for identification of bacteria and fungi by targeted DNA sequencing: CLSI guideline MM18 2nd ed Wayne Clinical and Laboratory Standards Institute 2018
26 Yoo JW Jo KW Kim MN Lee SD Kim WS Kim DS Increasing trend of isolation of non-tuberculous mycobacteria in a tertiary university hospital in South Korea Tuberc Respir Dis (Seoul) 2012 72 409 15 23101005
27 Park Y Kwak SH Yong SH Lee SH Leem AY Kim SY The association between behavioral risk factors and nontuberculous mycobacterial pulmonary disease Yonsei Med J 2021 62 702 7 34296547

상세보기
28 Roberts L How COVID is derailing the fight against HIV, TB and malaria Nature 2021 597 314 34508245
29 Amar S Avni YS O’Rourke N Michael T Prevalence of common infectious diseases after COVID-19 vaccination and easing of pandemic restrictions in Israel JAMA Netw Open 2022 5 e2146175 35103792

상세보기
30 Park YS Lee CH Lee SM Yang SC Yoo CG Kim YW Rapid increase of non-tuberculous mycobacterial lung diseases at a tertiary referral hospital in South Korea Int J Tuberc Lung Dis 2010 14 1069 71 20626955
31 Spaulding AB Lai YL Zelazny AM Olivier KN Kadri SS Prevots DR Geographic distribution of nontuberculous mycobacterial species identified among clinical isolates in the United States, 2009-2013 Ann Am Thorac Soc 2017 14 1655 61 28817307

상세보기
32 Lim AY Chotirmall SH Fok ET Verma A De PP Goh SK Profiling non-tuberculous mycobacteria in an Asian setting: characteristics and clinical outcomes of hospitalized patients in Singapore BMC Pulm Med 2018 18 85 29788943
33 Wu J Zhang Y Li J Lin S Wang L Jiang Y Increase in nontuberculous mycobacteria isolated in Shanghai, China: results from a population-based study PLoS One 2014 9 e109736 25330201

상세보기
34 Honda JR Virdi R Chan ED Global environmental nontuberculous mycobacteria and their contemporaneous man-made and natural niches Front Microbiol 2018 9 2029 30214436

상세보기
35 Zhang H Luo M Zhang K Yang X Hu K Fu Z Species identification and antimicrobial susceptibility testing of non-tuberculous mycobacteria isolated in Chongqing, Southwest China Epidemiol Infect 2020 149 e7 33436128
36 Zhang ZX Cherng BP Sng LH Tan YE Clinical and microbiological characteristics of non-tuberculous mycobacteria diseases in Singapore with a focus on pulmonary disease, 2012-2016 BMC Infect Dis 2019 19 436 31101082
37 Khieu V Ananta P Kaewprasert O Laohaviroj M Namwat W Faksri K Whole-genome sequencing analysis to identify infection with multiple species of nontuberculous mycobacteria Pathogens 2021 10 879 34358029

상세보기
38 Woodley CL Kilburn JO David HL Silcox VA Susceptibility of mycobacteria to rifampin Antimicrob Agents Chemother 1972 2 245 9 4670494

상세보기
39 Rosenzweig DY Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex: clinical features and course in 100 consecutive cases Chest 1979 75 115 9 421545
40 Etzkorn ET Aldarondo S McAllister CK Matthews J Ognibene AJ Medical therapy of Mycobacterium avium-intracellulare pulmonary disease Am Rev Respir Dis 1986 134 442 5 3752699

상세보기
41 Wallace RJ Dunbar D Brown BA Onyi G Dunlap R Ahn CH Rifampin-resistant Mycobacterium kansasii Clin Infect Dis 1994 18 736 43 8075262

상세보기
42 Griffith DE Brown-Elliott BA Langsjoen B Zhang Y Pan X Girard W Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease Am J Respir Crit Care Med 2006 174 928 34 16858014

상세보기
43 Brown-Elliott BA Iakhiaeva E Griffith DE Woods GL Stout JE Wolfe CR In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates J Clin Microbiol 2013 51 3389 94 23946523

상세보기
44 Jeon K Kwon OJ Lee NY Kim BJ Kook YH Lee SH Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients Am J Respir Crit Care Med 2009 180 896 902 19661243

상세보기
45 Koh WJ Hong G Kim SY Jeong BH Park HY Jeon K Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen Antimicrob Agents Chemother 2013 57 2281 5 23478956

상세보기
46 Brown-Elliott BA Woods GL Antimycobacterial susceptibility testing of nontuberculous mycobacteria J Clin Microbiol 2019 57 e00834 19 31315954

상세보기
47 Jaffre J Aubry A Maitre T Morel F Brossier F Robert J Rational choice of antibiotics and media for Mycobacterium avium complex drug susceptibility testing Front Microbiol 2020 11 81 32140138

상세보기
48 Huang WC Yu MC Huang YW Identification and drug susceptibility testing for nontuberculous mycobacteria J Formos Med Assoc 2020 119 Suppl 1 S32 41 32423573
49 Liu CF Song YM He WC Liu DX He P Bao JJ Nontuberculous mycobacteria in China: incidence and antimicrobial resistance spectrum from a nationwide survey Infect Dis Poverty 2021 10 59 33926548

상세보기
50 Cho EH Huh HJ Song DJ Moon SM Lee SH Shin SY Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens J Infect Chemother 2018 24 315 8 29223615
51 Moon SM Choe J Jhun BW Jeon K Kwon OJ Huh HJ Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease Respir Med 2019 148 37 42 30827472

상세보기
52 da Silva Telles MA Chimara E Ferrazoli L Riley LW Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates J Med Microbiol 2005 54( Pt 10 975 9 16157553
53 Cho EH Huh HJ Song DJ Lee SH Kim CK Shin SY Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens Diagn Microbiol Infect Dis 2019 93 107 11 30236529

상세보기
54 Nash KA Brown-Elliott BA Wallace RJ A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae Antimicrob Agents Chemother 2009 53 1367 76 19171799

상세보기

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증